探讨住院前口服华法林与院内尿激酶治疗超急性期脑梗死后脑出血发生的相关性

Explore the correlation between the incidence of cerebral hemorrhage in super acute cerebral infarction treated with urokinase and preadmission warfarin

目的探讨当在治疗起点检测INR<1.7时,对于接受尿激酶(UK)治疗的超急性期脑梗死患者,住院前1周内口服华法林与院内尿激酶治疗超急性脑梗死后脑出血发生的相关性。方法回顾性分析笔者所在医院2006年5月至2011年11月来使用尿激酶溶栓治疗超急性期脑梗死患者136例临床资料。根据患者住院前1周内是否使用华法林,分为2组,实验组住院前1周内使用过华法林,对照组住院前1周内未服用过华法林,分别记录治疗第1～15天的发生脑出血例数。结果实验组脑出血9例,脑出血发生率20.93%;对照组脑出血患者16例,脑出血发生率23.52%。用分类变量的关联性分析,P=0.7991>0.05,列联系数r无统计学意义。结论当在治疗起点检测INR<1.7时,住院前口服华法林与院内尿激酶治疗缺血性脑卒中后脑出血率的没有相关性。

Objective Investigate the correlation between the incidence of cerebral hemorrhage in super acute cerebral infarction treated with urokinase and preadmission warfarin use nearly a week with an international normalized ratio 〈 1.7. Methods 136 cases of clinical data from a retrospective analysis of the author＇ s hospital in May 2006 to November 2011, using thrombolytic therapy because of super acute cerebral infarction. patients were divided into two groups according to whether have the history warfarin preadmission use nearly a week. patients in the experimental group used warfarin nearly a week before admission, control group were nonusers, recorded the number of cases of cerebral hemorrhage from 1 day to 15 day treatment. Results Cerebral hemorrhage incidence was 20. 93% among warfarin users and 23.52% among nonusers. Conclusion The results from the present study suggest that preadmission warfarin use has no correlation with the incidence of cerebral hemorrhage in super acute cerebral infarction treated with urokinase when international normalized ratio 〈 1.7.